Abivax

Abivax is exploring a novel mechanism of action to enhance the expression of microRNA-124, a natural regulator of the inflammatory response in diseases like ulcerative colitis.

Obefazimod is an investigational, orally administered, once-daily therapy and the lead drug candidate from Abivax.

Abivax is looking forward to evolving into a commercial-stage company through opportunities to potentially harness the novel mechanism of action of obefazimod and beyond.

20191203_Abivax_Der Aktionaer_Convience Translation (ENG)[1]

View publications based on Abivax research or clinical investigation of lead drug candidate, obefazimod.

View congressional publications from medical meetings related to obefazimod, Abivax’s lead investigational drug candidate.

Abivax hosted a live industry symposium at UEG Week Virtual, chaired by Prof. Bruce Sands.

Abivax has an experienced leadership team with expertise in the scientific development and commercialization of therapeutics for chronic inflammatory diseases.

Abivax is a clinical-stage biotechnology company focused on harnessing the body’s natural regulatory mechanisms through enhanced expression of microRNA-124.

Abivax has a history of following the science and recognizing its potential to address unmet needs, which enables continuous exploration and future possibilities.

The Abivax mission is to harness the power of microRNA biology to create transformative treatments for patients in need.

Abivax operates headquarters and facilities in Paris, Montpellier, and Boston and is expanding its US team.

Abivax is a clinical-stage biotechnology company driven to advance human health by regulating the immune response through the power of microRNA.

Abivax’s Privacy Policy outlines how the company processes personal data collected via its website, social media, and other activities.

Abivax’s Privacy Policy explains how the company collects and processes personal data through its website, social media, and marketing activities.